LLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism

"This market is priced for perfection," says Rebecca Walser, and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight loss drug disappointed, though she believes there's more than enough market share for it to rebound. Andrew Wang agrees, adding that backing from the Trump administration "keeps me optimistic" on Eli Lilly's outlook.

Trading 360

07 Aug 2025

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
6:00 pm
The Wrap
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
ON AIR
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
11:00 pm
The Wrap
REPLAY